FDA accepts Genentech BLA for vamikibart in UME
Genentech said the FDA accepted its BLA for vamikibart in UME and that a decision is expected by July 2027, alongside shown 52-week Phase III data. The company also said filings in the EU, China, and Japan were accepted.